Opinion statement
Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction. Myasthenia crisis, defined as respiratory failure requiring mechanical ventilation in MG, is a common life-threatening complication that occurs in approximately 15% to 20% of patients with MG during their life time. The advent of effective mechanical ventilation, specialized neurointensive care units and the widespread use of immunotherapies have substantially altered the prognosis of myasthenic crisis. Early intubation and mechanical ventilation is perhaps the most important step in the management of myasthenic crisis. The authors favor an orotracheal approach for intubation, and placement of small bore duodenal tubes that may help decrease the risk of aspiration and may be more comfortable than regular nasogastric tubes for the patient. Plasma exchange may be more effective than the intravenous immunoglobulin in the treatment of myasthenic crisis involving respiratory failure. A randomized trial is required to confirm the superior efficacy of plasma exchange compared with intravenous immunoglobulin. In the acute setting, the role of immunosuppression and intravenous/intramuscular pyridostigmine and the newer agents such as tacrolimus remains limited and at times controversial. The therapy should be tailored at an individual basis using best clinical judgment.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Fink ME: Treatment of critically ill patient with myasthenia gravis. In Neurology and Neurosurgical Intensive Care, Edition 3. Edited by Ropper AH. New York: Raven Press; 1993:351–362.
Wilks S: On cerebritis, hysteria, and bulbar paralysis, as illustrative of arrest of function of the cerebrospinal centers. Guy’s Hospital Report 1877, 22:7–55.
Pascuzzi RM: The history of myasthenia gravis. Neurol Clin 1994, 12:231–242.
Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330:1797.
Phillips II LH: The epidemiology of myasthenia gravis. Neurol Clin 1994, 12:263–271.
Qureshi AI, Choudhry MA, Mohammad Y, et al.: Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monitor 2004, 10:CR684–689.
Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC: The Ice test versus the rest test in myasthenia gravis. Ophthalmology 2000, 107:1995–1998.
Lertchavanakul A, Gamnerdsiri P, Hirunwiwatkul P: Ice test for ocular myasthenia gravis. J med Assoc Thai 2001, 84(suppl 1):S131–136.
Hoch W, McConville J, Helms S, et al.: Auto-antibodies to the receptor tyrosine kinase musk in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365–368.
Wilkins KB, Bulkley GB: Thymectomy in the integrated management of myasthenia gravis. Adv Surg 1999, 32:105–133.
Bedlack RS, Sanders DB: How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med 2000, 107:211–214.
Mayer SA: Intensive care of the myasthenic patient. Neurology 1997, 48:70–75S. This is a nice review of the topic from an expert in this field.
Berrouschot J, Baumann I, Kalischewski P, et al.: Therapy of myasthenic crisis. Crit Care Med 1997, 25:1228–1235.
Thomas CE, Mayer SA, Gungor Y, et al.: Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997, 48:1253–1260.
Qureshi Al, Bhardwaj A, Ulatowski JA: Neurocritical care for the house officer. In ICU Care House Officer Series. Edited by Helfaer M. Baltimore: Williams & Wilkins; 1998:65, 92. This is a good review for the neurologists in training or those specialists not involved with neuromuscular care directly.
Janjua N, Mayer SA: Myasthenic crisis. In Critical Care Neurology and Neurosurgery, Edition 1. Edited by Suarez JI. New Jersey: Humana Press; 2004:469–480. This book is by far one of the most comprehensive efforts on elaborate management issues pertaining to neurocritical care. This particular chapter is an exhaustive review of the topic with very focused and practical management aspects discussed by the experts in the field of neurocritical care.
Younger DS, Raksadawan N: Therapy in neuromuscular disease. Neurol Clin 2001, 19:205–215.
Mayer SA, Thomas CE: Therapy of myasthenic crisis. Crit Care Med 1998, 26:1136–1137. This is another nice review on this topic.
London SFRS: Neuromuscular emergencies. In Emergent and Urgent Neurology. Edited by Weiner WJ. Philadelphia: JB Lippincott; 1992:59–78.
Rieder P, Louis M, Jolliet P, Chevrolet JC: The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995, 21:663–668.
Tripathi M, Kaushik S, Dubey P: The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. J Postgrad Med 2003, 49:311–314; Discussion 314–315.
Qureshi AI, Choudhry MA, Akbar MS, et al.: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629–632. There is a lack of major trials and evidence based treatment options for patients with myasthenia. This paper deals with a small number of patients but represents an excellent effort to address this important question.
Gajdos P, Chevret S, Clair B, et al.: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol 1997, 41:789–796. This is another effort to address a very similar question represented in a relatively small subset of patients.
Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic crisis: Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993, 50:837–840.
Qureshi AI, Suri MF: Plasma exchange for treatment of myasthenia gravis: Pathophysiologic basis and clinical experience. Ther Apher 2000, 4:280–286. This is a good review for plasma exchange option in myasthenia gravis. The authors represent their own clinical experience in a practical and evidence-based approach.
Wolfe GI, Barohn RJ, Foster BM, et al.: Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002, 26:549–552.
Confavreux C, Saddier P, Grimaud J, et al.: Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology 1996, 46:1607–1612.
Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003, 998:494–499.
Meriggioli MN, Rowin J: Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol 2003, 20:382–385.
De Feo LG, Schottlender J, Martelli NA, Molfino NA: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002, 26:31–36.
Takamori M, Motomura M, Kawaguchi N, et al.: Antiryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004, 62:1894–1896.
Utsugisawa K, Nagane Y, Yonezawa H, et al.: Effects of fk506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve 2003, 27:245–248.
Evoli A, Di Schino C, Marsili F, Punzi C: Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002, 25:111–114.
Gordon MY, Goldman JM, Gordon-Smith EC: 4-hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985, 9:1017–1021.
Jones RJ, Barber JP, Vala MS, et al.: Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85:2742–2746.
Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide. Ann Neurol 2003, 53:29–34. This is an innovative, but unproven approach to treat refractory MG.
Romi F, Gilhus NE, Varhaug JE, et al.: Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Ann N Y Acad Sci 2003, 998:481–490.
Wolfe GI, Kaminski HJ, JaretzkiIII A, et al.: Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 2003, 998:473–480.
Kissel JT, Franklin GM: Treatment of myasthenia gravis: A call to arms. Neurology 2000, 55:3–4. In this paper there is good effort and an attempt on highlighting the importance of seriousness of this disease process and urgency of promoting better research on this topic both in the clinical and basic care setting.
Soleimani A, Moayyeri A, Akhondzadeh S, et al.: Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. BMC Neurol 2004, 4:12.
Cohen MS, Younger D: Aspects of the natural history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci 1981, 377:670–677. A good review of natural history of myasthenia gravis and myasthenic crisis.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ahmed, S., Kirmani, J.F., Janjua, N. et al. An update on myasthenic crisis. Curr Treat Options Neurol 7, 129–141 (2005). https://doi.org/10.1007/s11940-005-0022-2
Issue Date:
DOI: https://doi.org/10.1007/s11940-005-0022-2